June 22, 2020
IRAKIMiDs: Protein degraders targeting both IRAK4 and IMiD substrates show combinatorial effects leading to broad activity with durable regressions in MYD88 mutant lymphoma xenografts in vivo
American Association for Cancer Research (AACR) Virtual Annual Meeting II
Other
Read More
June 22, 2020
A STAT3-selective targeted protein degrader decreases the immune-suppressive tumor microenvironment and drives anti-tumor activity in preclinical models
American Association for Cancer Research (AACR) Virtual Annual Meeting II
Other
Read More
February 5, 2020
Identification of highly potent and selective Interleukin-1 receptor associated kinase 4 (IRAK4) degraders for the treatment of hidradenitis suppurativa
European Hidradenitis Suppurativa Foundation Scientific Conference
Hidradenitis Suppurativa (HS)
Read More
December 7, 2019
Small molecule-induced, selective STAT3 degradation leads to anti-tumor activity in STAT3-dependent heme malignancies
American Society of Hematology (ASH) Annual Meeting
Other
Read More
November 8, 2019
A first-in-class selective and potent IRAK4 degrader demonstrates robust in vitro and in vivo inhibition of TLR/IL-1R activation and inflammation
American College of Rheumatology Annual Meeting
Read More
October 26, 2019
Discovery of KYM-003, a potent and selective STAT3 degrader with anti-tumor activity in heme malignancies
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Other
Read More
June 18, 2019
IRAK4 degraders for MYD88 mutant lymphoma
International Conference on Malignant Lymphoma (ICML)
Other
Read More
March 29, 2019
KYM-001, first-in-class oral IRAK4 protein degraders, induce tumor regression in a xenograft model of MYD-88 mutant ABC DLBCL alone and in combination with BTK inhibition
American Association for Cancer Research (AACR) Annual Meeting
Other
Read More
January 28, 2019
Targeted Protein Degradation Mechanisms
Zhang, Y., Loh, C., Chen, J., & Mainolfi, N. (2019). Targeted protein degradation mechanisms. Drug Discovery Today: Technologies, 31, 53-60.
Read More
December 1, 2018
Targeted degradation of IRAK4 protein via heterobifunctional small molecules for treatment of MYD88 mutant lymphoma
American Society of Hematology (ASH) Annual Meeting
Other
Read More